Latest news

• Industry aghast as EU Parliament backs biosimilar rule change

  In an open letter to European institutions, the president of the EFPIA trade body, Merck KGaA chairman and CEO Stefan Oschmann (below), says the EP’s provisions “diverge significantly from the

• Vertex an “extreme outlier” in pricing and behaviour, says NHS England

  A letter from John Stewart, National Director, Specialised Commissioning at NHS England to Dr Wollaston shows there is still no love lost at the health service budget holder when it comes ... This culminated in Vertex’s chief executive taking a highly

• Vertex to Theresa May: Orkambi verdict ‘threatens bio investment’

  CEO writes open letter to prime minister. Fresh from the news that the NHS in England still isn’t minded to fund treatment with its cystic fibrosis therapy Orkambi, Vertex Pharma ... The letter to Theresa May asks for her “urgent intervention” in

• Moving times

  At the end of August, a group of LGBT EMA employees wrote an open letter to Guido Rasi (executive director of the EMA), Donald Tusk, Jean-Claude Juncker and Antonio Tajani ... affected by the EMA relocation.’ Naturally the letter does not cite any

• EU and UK pharma leaders appeal directly to Brexit negotiators

  Eight associations from the UK and Europe have written an open letter to the negotiators to plead for an early partnership agreement on medicines, saying that drugs could be "held either ... An implementation period that adequately reflects the time